Mesa Laboratories (NASDAQ:MLAB) Rating Lowered to Buy at Wall Street Zen

Key Points

• Wall Street Zen downgraded Mesa Laboratories from “strong buy” to “buy.” Other analysts remain cautious, with the stock carrying an average “hold” rating and a consensus price target of $110.
• Mesa Laboratories reported quarterly earnings of $2.68 per share on revenue of $60.14 million. Shares opened at $106.04, while the company trades at a high price-to-earnings ratio of 126.24.
• Insiders sold 8,277 shares worth approximately $770,000 during the last quarter, while institutional investors own a substantial 90.6% of outstanding shares.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Saturday.

A number of other equities analysts also recently commented on the stock. Weiss Ratings upgraded shares of Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a report on Tuesday. Wells Fargo & Company raised their price target on shares of Mesa Laboratories from $94.00 to $110.00 and gave the company an "equal weight" rating in a report on Friday. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $110.00.

Mesa Laboratories Stock Down 6.3%

Shares of NASDAQ MLAB opened at $106.04 on Friday. Mesa Laboratories has a 12-month low of $58.83 and a 12-month high of $115.52. The stock's fifty day simple moving average is $100.64 and its two-hundred day simple moving average is $95.97. The stock has a market capitalization of $593.82 million, a PE ratio of 126.24 and a beta of 0.92. The company has a current ratio of 1.79, a quick ratio of 1.29 and a debt-to-equity ratio of 0.73.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 EPS for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.The firm had revenue of $60.14 million during the quarter.

Insider Transactions at Mesa Laboratories

In other news, CFO John Sakys sold 2,827 shares of the firm's stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the sale, the chief financial officer owned 19,785 shares of the company's stock, valued at $1,770,757.50. This trade represents a 12.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of the business's stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $39,559.00. Following the transaction, the chief accounting officer owned 2,020 shares in the company, valued at approximately $180,790. This trade represents a 17.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,277 shares of company stock valued at $770,122 in the last quarter. 2.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mesa Laboratories

A number of large investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. raised its position in shares of Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Mesa Laboratories in the 4th quarter worth approximately $27,000. Kestra Advisory Services LLC purchased a new stake in Mesa Laboratories during the 4th quarter worth approximately $55,000. BNP Paribas Financial Markets grew its position in Mesa Laboratories by 30.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 243 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier's stock valued at $79,000 after purchasing an additional 684 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company's stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source